# Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

> **NCT03374332** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Brown University** · enrollment: 11 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Gemtuzumab Ozogamicin (GO)
- **OTHER:** Donor Leukocytes

## Key facts

- **NCT ID:** NCT03374332
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-31
- **Primary completion:** 2023-09-26
- **Final completion:** 2024-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2024-02-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03374332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03374332, "Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03374332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*